T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Vemurafenib (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Tumour infiltrating lymphocytes
- Indications Malignant melanoma
- Focus Adverse reactions
- 16 Mar 2018 Planned End Date changed from 1 Nov 2017 to 1 Aug 2020.
- 16 Mar 2018 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated